Mutual knowledge exchange central
to this year’s scientific programme
Delegates attending this year’s EULAR Congress in Madrid can expect to take their pick from a dynamic scientific programme that promises to deliver the
latest research across a wide spectrum of paediatric and adult rheumatologic diseases.
Chair of this
Thomas Dörner, a
Hospitals, Berlin, said one key
previous years is
that this year’s
Congress is a joint initiative between
EULAR and the Paediatric Rheumatology European Society (PReS).
“We wanted to demonstrate a consistency between paediatric and adult
rheumatology because most children
will need to transition into adult rheumatology services. Both fields have
some differences and similarities
from pathogenic aspects, diagnostic
approaches through treatment mo-dalities,” Prof. Dörner explained in an
According to Prof. Dörner, another
exciting element of this year’s programme is that it offers – perhaps
for the first time in a long time – a
balance of the speed of recent developments across the entire domain
of diseases, including infrequent
(orphan) diseases that fall under the
umbrella of rheumatology.
“This year we have 38 topic domains, and delegates will get to learn
about not only new developments
in inflammatory arthritis, psoriatic
arthritis, and ankylosing spondylitis
but also in systemic autoimmune diseases such as lupus, Sjögren’s syndrome, antiphospholipid syndrome,
and systemic sclerosis,” he said.
“We will also see advances in such
areas as osteoarthritis, osteoporosis,
and fracture prevention. This is good
... we don’t have such an imbalanced
programme, where one area makes
progress and the other is left behind,”
Just under 5,000 abstracts were
received this year
by the Abstract
mittee. Of these,
360 (7%) will be
presented in oral
the link with
Epidemiological aspects of rheumatic
diseases also made a strong show-
ing this year,” said Prof. John Isaacs,
who is Chair of the Abstract Selection
Around 45% of the abstracts received will be presented as poster
communications across all themes
included in the EULAR scientific
programme, said Prof. Isaacs, who
is also professor of clinical rheumatology and director of the Institute of
Cellular Medicine at Newcastle University, Newcastle upon Tyne, United
“There is something for everyone,
as there is at least one poster tour for
each category of submitted abstracts.
Poster tours are very popular, so delegates will need to register early to
obtain one of the limited places,” he
A high point of the scientific programme is Wednesday’s opening
plenary abstract session featuring
this year’s top-scoring abstracts handpicked by the scientific committee.
Prof. Isaacs’s highlights from this
session include the latest results from
the SENSCIS trial on nintedanib in
patients with systemic sclerosis–
associated interstitial lung disease; and
the gastrointestinal, liver, renal, and
cardiovascular adverse effects of
paracetamol; and a potential epigenetic therapeutic target for osteoarthritis.
This year delegates also can look
forward to even more high-quality
abstracts presented in a late-breaking
oral session early Saturday morning.
“Last year we introduced the submission of late-breaking abstracts,
which was a little bit underused, but
this year, we had almost 30 abstract
submissions that were of very high
quality,” Prof. Dörner said.
One study to look for at this session includes 24-week results from
the use of the monoclonal antibody
tanezumab in osteoarthritis.
Other late-breaker topics of note,
according to Prof. Isaacs, include the
first phase 3 results of filgotinib, the
results of an implantable vagus nerve
stimulator in RA patients, and a randomised, controlled trial of “ultralow”
doses of rituximab for re-treatment
cycles in RA.
A notable clinical session also taking place on Wednesday is the What
Is New (WIN) session presented by
Prof. Francis Berenbaum of France
on osteoarthritis management, Prof.
“In previous years, progress in the
management and treatment of osteoarthritis has been at a slower pace,
compared to other diseases, but this
year the programme has several exciting sessions relating to progress
in the field, particularly in terms of
medical treatment,” he said.
Also on Wednesday, Prof. Berenbaum will chair a clinical science session on the pharmaceutical pipeline in
osteoarthritis along with Prof. Philip
Prof. Dörner Prof. Isaacs